Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients

Journal of Clinical Psychopharmacology

Volumn 18, Issue 4, 1998, Pages 305-310

  Nordström, Anna Lena ^a   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0031948076     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199808000-00010     Document Type: Article

References (36)

1. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
2. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-44.
3. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
4. Rubin RT. Prolactin and schizophrenia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:803-8.
5. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33: 279-86.
6. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 1983;1983:271-83.
7. Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 1980;5:121-37.
8. Poland RE, Rubin RT. Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin. Life Sci 1981;29:1837-45.
9. Laughren TP, Brown WA, Williams BW. Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am J Psychiatry 1979;136:108-10.
10. Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurol Clin 1988;6:213-23.
11. Johnson GFS, Hunt GE. The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels. Aust N Z J Psychiatry 1980;14:127-31.
12. Wiles D, Franklin M, Dencker SJ, Johansson R, Lundin L, Malm U. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology (Berl) 1980;71:131-6.
13. Van Putten T, Marder SR, Mintz J. Serum prolactin as correlate of clinical response to haloperidol. J Clin Psychopharmacol 1991;11: 357-61.
14. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
15. Köhler C, Hall H, Ögren S, Gawell L. Specific in vitro and in vivo binding of 3H-raclopride, a potent substituted drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 1985;34:2251-9.
16. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berl) 1986;90:287-94.
17. 2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 1988;94:1-7.
18. Litton J, Bergström M, Eriksson L, Bohm C, Blomqvist G, Kesselberg M. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assisted Tomogr 1984;8:74-87.
19. Litton JE, Holte S, Eriksson L. Evaluation of the Karolinska New Positron Camera System: the Scanditronix PC2048-15B. IEEE Trans Nucl Sci 1990;37:743-8.
20. 11C]raclopride binding in healthy subjects and schizophrenic patients: reliability and age effects. Hum Psychopharmacol 1992;7:157-65.
21. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int J Rad Appl Instrum [B] 1991;18:871-81.
22. Greitz T, Bergström M, Boëthius J, Kingsley D, Ribbe T. Head fixation system for integration of radiodiagnostic and therapeutic procedures. Neuroradiology 1980;19:1-6.
23. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:213-9.
24. Movin-Osswald G, Nordström A-L, Hammarlund-Udenaes M, Wahlén A, Farde L. Pharmacokinetics of raclopride with different formulations, and its influence on prolactin and side effects in healthy male volunteers. Clin Pharmacokinet 1992;22: 152-61.
25. Sassin JF, Frantz AG, Weitzman ED, Kapen S. Human prolactin 24-hour pattern with increased release during sleep. Science 1972;177:1205-7.
26. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708.
27. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992;106:433-8.
28. MINITAB reference manual, release 7. PA: Minitab, Inc.; Boston, MA: Prindle, Weber & Schmidt; April, 1989.
29. Belsley DA, Kuh E, Welsch RE. Regression diagnostics. New York: John Wiley and Sons, Inc., 1980.
30. Ganong WF. Circulation through Special regions. Review of medical physiology. 10th ed. Los Altos, CA: Lange Medical Publications, 1981:476-93.
31. Farde L, Sedvall G, Wiesel F-A, Hall H, Halldin C, Stone-Elander S. In reply to brain dopamine receptors in schizophrenia: PET problems. Arch Gen Psychiatry 1988;45:599-600.
32. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19:603-6.
33. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;1551-5.
34. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S. Clozapine plasma levels and prolactine response. Psychopharmacology (Berl) 1981;73:181-7.
35. 2 receptor occupancy in relation to clozapine serum concentration: a PET study in schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
36. Tollefson GD, Beasley CM, Tran PV, Street JS, Kreuger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.